Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fasanmade

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Annals of African Medicine|November 18, 2016
Performance of waist circumference and proposed cutoff levels for defining overweight and obesity in NigeriansChristian I Okafor, Taiwo H Raimi, Ibrahim D Gezawa, et al.
The Nigerian Postgraduate Medical Journal|March 16, 2007
Comparative study of the effect of tocotrienols and -tocopherol on fasting serum lipid profiles in patients with mild hypercholesterolaemia: a preliminary reportJ N A Ajuluchukwu, N U Okubadejo, M Mabayoje, et al.
Digital Health|January 13, 2023
Telemedicine ready or not? A cross-sectional assessment of telemedicine maturity of federally funded tertiary health institutions in NigeriaTolulope F Olufunlayo, Oluwadamilola O Ojo, Obianuju B Ozoh, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2015
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseM Rosario, N L Dirks, M R Gastonguay, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein, R H Diamond, C L Wagner, et al.
British Journal of Clinical Pharmacology|April 27, 2016
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairmentBaiteng Zhao, Robert Chen, Owen A O'Connor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancerG F Fleming, J W Kugler, P C Hoffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neckB Brockstein, D J Haraf, K Stenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue bindingPauline L Martin, Qun Jiao, Joel Cornacoff, et al.
Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Annals of African Medicine|November 18, 2016
Performance of waist circumference and proposed cutoff levels for defining overweight and obesity in NigeriansChristian I Okafor, Taiwo H Raimi, Ibrahim D Gezawa, et al.
The Nigerian Postgraduate Medical Journal|March 16, 2007
Comparative study of the effect of tocotrienols and -tocopherol on fasting serum lipid profiles in patients with mild hypercholesterolaemia: a preliminary reportJ N A Ajuluchukwu, N U Okubadejo, M Mabayoje, et al.
Digital Health|January 13, 2023
Telemedicine ready or not? A cross-sectional assessment of telemedicine maturity of federally funded tertiary health institutions in NigeriaTolulope F Olufunlayo, Oluwadamilola O Ojo, Obianuju B Ozoh, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2015
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseM Rosario, N L Dirks, M R Gastonguay, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein, R H Diamond, C L Wagner, et al.
British Journal of Clinical Pharmacology|April 27, 2016
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairmentBaiteng Zhao, Robert Chen, Owen A O'Connor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancerG F Fleming, J W Kugler, P C Hoffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neckB Brockstein, D J Haraf, K Stenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue bindingPauline L Martin, Qun Jiao, Joel Cornacoff, et al.
Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.
Pageof 10